Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2025

    Employees

    131

Stocks News & Analysis

stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks

Could merger breathe new life into struggling ASX asset manager?

Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,815.305.00-0.06%
CAC 407,808.1721.12-0.27%
DAX 4024,160.6494.67-0.39%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,998.0656.940.64%
HKSE24,203.3263.750.26%
NASDAQ20,640.3354.800.27%
Nikkei 22539,459.62110.06-0.28%
NZX 50 Index12,678.697.99-0.06%
S&P 5006,268.568.810.14%
S&P/ASX 2008,570.409.70-0.11%
SSE Composite Index3,519.659.470.27%

Market Movers